Printer Friendly

FDA APPROVES NEW P&G PRESCRIPTION DRUG

 FDA APPROVES NEW P&G PRESCRIPTION DRUG
 CINCINNATI, Jan. 6 /PRNewswire/ -- The Procter & Gamble Company


(NYSE: PG) announced today that the U.S. Food and Drug Administration (FDA) has approved Macrobid (nitrofurantoin monohydrate/macrocrystals) for the treatment of acute uncomplicated urinary tract infection (UTI) due to E. coli and S. saprophyticus, two strains of common bacteria. P&G's subsidiary, Norwich Eaton Pharmaceuticals, Inc., will begin selling the prescription product as soon as possible.
 Uncomplicated UTI is a disease which affects one in five women during their lifetime. P&G has worked closely with the FDA to gain approval for Macrobid and acknowledged the agency's timely review of its new drug application for this product. Approval for Macrobid took just 20 months from the date of filing.
 Macrobid has been studied extensively in more than 35 centers worldwide and has been proven to be safe and effective.
 Macrobid is a twice-daily dosage formulation of nitrofurantoin. Norwich currently markets Macrodantin (nitrofurantoin macrocrystals), which is taken four times a day. Macrodantin is the leading brand name urinary tract antibacterial prescription drug. After 23 years on the market, its usage continues to grow.
 Macrobid features a patented delivery system that provides a more convenient twice-daily dosage. This benefit, combined with the clinical efficacy of nitrofurantoin, makes Macrobid a welcome new option for sufferers of acute uncomplicated UTIs due to susceptible organisms -- the most common type of infection among women.
 Procter & Gamble had sales of $27 billion during fiscal 1990-91. P&G makes and markets a wide range of products for consumers and industry, including over-the-counter and prescription health care products. Norwich Eaton Pharmaceuticals is responsible for the company's growing prescription drug business.
 -0- 1/6/92
 /CONTACT: Ruth Behrens of Norwich Eaton, 607-335-2531; or Teri Glover of Procter & Gamble, 513-983-1351/
 (PG) CO: Procter & Gamble ST: Ohio IN: HOU SU:


KK -- CL004 -- 6882 01/06/92 11:43 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 6, 1992
Words:314
Previous Article:TEXTRON LYCOMING TO PARTICIPATE IN ROLLS-ROYCE TAY 670 ENGINE PROGRAM
Next Article:APA OPTICS DELIVERS ITS FIRST INTERFEROMETER FOR ASPHERIC TESTING
Topics:


Related Articles
FDA ISSUES IMPORT ALERT AGAINST UNAPPROVED MAIL-ORDER DRUGS
WHITEHALL LABORATORIES REAFFIRMS ITS COMMITMENT TO CHILD RESISTANT CLOSURES
CPSC Issues NPR for Over the Counter Drugs.
Mail-order Rx firms broker cheap drugs.
Adams Laboratories, Inc. Comments on FDA's Follow-Up Statement to Enforcement Policy for Unapproved Long-Acting, Single-Entity Guaifenesin; - By...
Addressing a $20 Billion/Year Problem, PPLA Will Testify Before FDA On Consumer-Friendly Printed Information for All Rx Drugs; Trade Group Joins...
Drug reimportation debate is still heating up: any new drug reimportation legislation needs to ensure that reimported drugs are FDA approved.
Feds delay OTC decision for Plan B.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters